BGM Group Ltd. (BGM) Stock Score, Valuation & Financial Research
BGM Group Ltd. is in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 29/100.
Quick answer for BGM
BGM Group Ltd. currently has a Wall Street Score of 29/100. The stored market price is $0.26. Its financial score is 39/100. Its valuation score is 0/100. The latest WSS change is -0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What BGM Group Ltd. does
Operating from Chengdu, People's Republic of China, BGM Group Ltd. engages in the manufacturing and supply of active pharmaceutical ingredients (APIs), traditional Chinese medicine (TCM) derivatives, and various other related products across China. The company's pharmaceutical portfolio includes an array of licorice-based items: Gan Di Xin, an oral medication for cough and expectorant relief; Qilian Shan Licorice Extract, serving as a raw material for pharmaceutical firms to produce conventional licorice tablets; and Qilian Shan licorice liquid extract, a key ingredient utilized by medical preparers for crafting compound licorice oral solutions. BGM also provides Qilian Shan oxytetracycline tablets, formulated to prevent and treat a range of ailments in poultry (chickens, turkeys), livestock (cattle, swine), and humans, in addition to Qilian Shan oxytetracycline APIs for use by pharmaceu
BGM financial snapshot
- Wall Street Score:
- 29/100
- Current price:
- $0.26
- Market capitalization:
- $98.2M
- Revenue:
- $74.8M
- Net income:
- $-21.7M
- Free cash flow:
- $-4.4M
- Cash:
- $11.5M
- Total debt:
- $1.2M
- EPS:
- -0.13
- Financial score:
- 39/100
- Valuation score:
- 0/100
- Revenue score:
- 27/100
What stands out
- Reported year-over-year revenue growth is +1.0%.
- Free cash flow is $-4.4M, showing cash burn in the current stored period.
- The balance sheet shows $11.5M of cash versus $1.2M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is -0.1 points: BGM decreased 0.1 points because some fundamentals weakened.
- The current research record carries a corporate distress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 39/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research BGM
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.